By Futuristics: Keryx ( KERX ) recently declared successful results from its phase II study of renal disease drug "Zerenex" in non-dialysis dependent chronic
trial evidence, well-defined markets, and an ability of the drug to address more than one indication. With regard to Keryx ( KERX ), analysts have recently raised their price targets on the stock as the company's phosphate binder, Zerenex, continues
By EnhydrisPECorp : Shares of Zalicus ( ZLCS ) are down more than 25% since my last article outlining the risks and rewards of playing the company's pending Phase II trial results for Z160. To recap, Z160 is a first in class, oral, state dependent, selective N-type calcium channel (Cav 2.2) blocker
Keryx investors. Yesterday's upgrade by JPMorgan from $14 per share to $22 is just icing on the top. Keryx Biopharmaceuticals ( KERX ), a fast rising biotechnology company, witnessed an almost 22% increase since start of November, following
Keryx Biopharmaceuticals , Inc. ( KERX ) Q3 2013 Earnings Conference ..... Greetings and welcome to the Keryx Biopharmaceuticals Investor Conference Call ..... com/article/1810142- keryx - biopharmaceuticals -ceo-discusses-q3
In case shares of Keryx Biopharmaceuticals ( KERX +21.2% ) needed another shot in the arm, market chatter suggests Brean is out with a $26 target (so, a 100% upside basically
By PropThink: By Jake King Keryx Biopharmaceuticals ( KERX ) announced on Tuesday that a ..... PropThink suggested going long KERX in anticipation of positive CKD ..... Nephrology's Kidney Week meeting. KERX is up 25% to $13.50 on Tuesday
Top 10 Gainers: CYTX +68% . OXBT +42% . ENDP +28% . RBCN +26% . PMC +26% . KERX +21% . OSN +20% . GTAT +20% . YRCW +19% . AEIS +17% . Top 10 Losers: DXM -27% . BSFT -23% . IMGN -21% . NQ -20
(Reuters) - Keryx Biopharmaceuticals Inc's kidney drug proved effective in treating chronic kidney disease patients not on dialysis, sending the company's shares to a seven-year high on hopes the...
Gainers: CYTX +39% . ENDP +24% . GTAT +21% . KERX +18% . WAVX +13% . RBCN +11% . OTIV +10% . SB +9% . AEZS +10% . OTEX +8% . Losers: BSFT -20% . OWW -16% . IMGN -14% . LF -11% . MDR -6% . Post your comment!